Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Multicenter, Two-Cohort Study of Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan in Patients With Leptomeningeal Metastases From Solid Tumors

NCT07833657 is registered in ClinicalTrials.gov with Jiuda Zhao as lead sponsor.

NCT NCT07833657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07833657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Multicenter, Two-Cohort Study of Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan in Patients With Leptomeningeal Metastases From Solid Tumors
Lead sponsor
Jiuda Zhao
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2030
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leptomeningeal metastases, solid tumors